Steve Abrams
Partner
Philadelphia

Biography
As Global Co-Head of our Life Sciences & Health Care
industry sector, Steve Abrams works with clients inmany areas of the life sciences ecosystem, such as
oncology therapies, pain products, dermatology
therapies, vaccines, diagnostics, medical devices anddrug/device combinations, orphan drugs, and genetherapies. He also counsels a variety of companies thatprovide services to the life sciences industry.

Phone

Steve has successfully negotiated and completed arange of life sciences transactions, with a particularfocus on capital market offerings (IPOs, follow-on
offerings, ATMs, RDOs, PIPES, and private placements),
collaboration/licensing transactions, and M&Atransactions. Additionally, he regularly advises publicand privately held clients, including boards of directors,
on securities, governance, transactional, and a range ofother complex issues.

Practices

Steve is a member of the board of directors of inTEST
Corporation (NASDAQ: INTT), and a member of its
Audit and Compensation Committees. He is Chair of its
Nominating Committee as well. Steve has lectured in
front of various groups and published articles onsecurities, governance, and M&A issues.

+1 267 675 4671

Fax
+1 267 675 4601

Emailsteve.abrams@hoganlovells.com

Mergers and Acquisitions
Corporate Governance and PublicCompany Representation
Capital Markets
Securities and Public Company
Advisory
CommercialIndustries
Life Sciences and Health Care
Private Capital

Representative experience
A commercial-stage pharmaceutical company in its
US$46m follow-on offering led by Cowen and Cantor
Fitzgerald.

Areas of focus
Shareholder Activism
Cross-border Mergers andA commercial-stage pharmaceutical company in its
US$100m and US$50m follow-on offerings led byJefferies, Cowen, and Piper Jaffray.

An Australian-based clinical-stage pharmaceuticalcompany in its US$40m private placement.

Acquisitions
Hostile Takeovers and Takeover
DefensePublic Company Mergers andAcquisitions
Special Committee and Independent
Director Representations
Cell, Tissue, and Gene Therapies
Licensing and CommercialTransactions

A clinical-stage biotechnology company in its US$40m
and US$30m follow-on offerings and its US$35m atthe-market offering.

Education and admissions

A commercial-stage pharmaceutical company in its
US$70m follow-on offering and US$90m at-themarket offering.
A clinical-stage pharmaceutical company in its US$50m
at-the-market offering.

A publicly traded biotechnology company in its
US$63m sale.
A publicly traded commercial-stage pharmaceuticalcompany in an acquisition of a privately held specialty
pharmaceutical company.
A pre-clinical-stage pharmaceutical company in its
US$48m IPO of common stock through a syndicate ofunderwriters led by Jefferies and Piper Jaffray.*A clinical-stage pharmaceutical company in its US$80m
IPO of common stock through a syndicate ofunderwriters led by Jefferies and Piper Jaffray.*
A NASDAQ Global Market developer and supplier ofinjectable drug delivery systems in a US$45m
underwritten offering of common stock.*A clinical-stage biopharmaceutical company in its
US$40m at-the-market equity program led by Cowenand Company.*
A publicly traded clinical-stage pharmaceuticalcompany in a US$65.6m underwritten offering ofcommon stock.*
A provider of integrated clinical documentation
solutions for the U.S. health care system in a US$130m
acquisition.*

Education
J.D., University of Pennsylvania Law
School, cum laude, 1995
A.B., Johann Wolfgang GoetheUniversität Frankfurt am Main, test,
1992
B.A., Rutgers, The State University of
New Jersey, summa cum laude,1990

Bar admissions andqualifications
Pennsylvania
New Jersey

Accolades'He is one of the most clientfocused, knowledgeable andpersonable people I have workedwith.'

Clients quoted in Chambers USA
2024

A provider of integrated promotional outsource
services to life sciences companies in its US$55m
acquisition.*
A specialty pharmaceutical company in its US$138m
IPO of common stock through a syndicate ofunderwriters led by Jefferies and Piper Jaffray.
A specialty pharmaceutical company in its acquisitionof a commercial-stage specialty pharmaceuticalcompany and related equity and debt financing.
A clinical-stage oncology company in its reverse
merger into a NASDAQ-listed public company.
A specialty pharmaceutical company in its copromotional agreement with a major orthopaediccompany.
A commercial-stage specialty pharmaceutical company
in its US$120m follow-on public offering through a
syndicate of underwriters led by Jefferies and Piper
Jaffray.
Arbutus Biopharma Corp. on an at-the-market equity
offering led by Jefferies.
*Matter handled prior to joining Hogan Lovells.

Awards and rankings
Corporate/M&A: Securities (Pennsylvania), Chambers
USA, 2022-2024
Finance: Capital Markets: Equity Offerings,Recommended, Legal 500 US, 2017-2018, 20202024
Healthcare: Life Sciences, Recommended, Legal 500
US, 2021-2023
Corporate and M&A, Notable Practitioner, IFLR1000,
2020
Pharmaceuticals and life sciences, NotablePractitioner, IFLR1000, 2020
Life Sciences Star, LMG Life Sciences, 2018-2019

Latest thinking and events
News'Steve Abrams ... stand[s] out for[his] expertise representing small to
mid-sized public biotech andpharma companies.'

Client quoted in Legal 500 US 2022:
Healthcare – Life Sciences'Steve Abrams ... stand[s] out for[his] outstanding client service,tremendous level of experience andexpertise, and business-savvy legalrepresentation.'

Client quoted in Legal 500 US 2022:
Capital Markets – Equity Offerings
Steven Abrams is a highly-regarded
securities practitioner who regularly
handles cross-border mandates.

Chambers USA 2023
'Steven is exceptionally responsiveand helpful.' ... 'One of the mostprominent securities lawyers in themarket.'

Clients quoted in Chambers USA
2023

Mandatory compliance nears for remaining Section
13 reporting requirements
NewsSEC, whistleblowers and impact on employmentrelated agreements
Press releases
Hogan Lovells Guides Mind Medicine Inc. on its
US$75m Underwritten Public Offering
Press releases
Hogan Lovells advises Perspective Therapeutics inits US$80 million underwritten offering of equity
securities
Press releases
Hogan Lovells represents Optinose in its US$55
million registered direct offering
News2024 Life Sciences & Health Care Horizons